Effect of Intravenous Iron Supplementation on Celiac Disease Remission (IRONCEL)
NCT05114278 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 204
Last updated 2022-01-19
Summary
The study aims is to evaluate the efficacy of intravenous iron supplementation on celiac disease remission (total intestinal mucosal recovery). This randomized multicenter trial compare the administration of intravenous iron by infusion (Ferinject©: 15 mg/kg in NaCl solution in 30 min) and oral iron in combination; to patients receive only oral iron as standard care.
The first benefit with IV Iron supplementation is to correct iron deficiency more rapidly than oral iron alone because of trouble of absorption in case of intestinal villous atrophy.
Conditions
Interventions
- DRUG
-
Ferinject
Experimental group will receive intravenous iron infusion (Ferinject©: 15 mg/kg in NaCl solution IV) at randomization, 2weeks after randomization, 4weeks after randomization, and then every month for a total of one year. Comparison group will not receive any intravenous treatment. Both experimental and comparison groups will receive an oral iron supplementation (100 mg/day).
- DRUG
-
oral iron
All patients will receive an oral iron supplementation (100mg/day).
Sponsors & Collaborators
-
Ministry of Health, France
collaborator OTHER_GOV -
Assistance Publique - Hôpitaux de Paris
lead OTHER
Principal Investigators
-
Georgia MALAMUT, MD, PhD · Cochin, AP-HP, Paris
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-02-15
- Primary Completion
- 2026-04-15
- Completion
- 2026-04-15
Countries
- France
Study Locations
More Related Trials
-
Iron Deficiency and TTG Normalization
NCT05675280 ·Status: COMPLETED
-
Multicenter Study on the Toxicity of Gluten Traces in the Treatment of Celiac Disease
NCT00250146 ·Status: TERMINATED ·Phase: NA
-
Effects of a Nutritional Solution to Improve Intestinal Permeability in Celiac Patients
NCT03483805 ·Status: COMPLETED ·Phase: NA
-
Treatment of Screen-detected Celiac Disease
NCT01116505 ·Status: COMPLETED ·Phase: NA
-
Intestinal Permeability, Nutritional Status and Quality of Life in Celiac Disease
NCT04351828 ·Status: COMPLETED
-
Study of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal
NCT00669825 ·Status: COMPLETED ·Phase: PHASE1
-
Can a Very High Result From a Screening Test for Celiac Disease be Used to Diagnose Celiac Disease?
NCT00175760 ·Status: COMPLETED
-
Intestinal Fatty Acid-binding Protein (I-FABP) Levels in Pediatric Celiac Patients
NCT03244254 ·Status: UNKNOWN
-
Lymphocytic Enteritis and Suspected Coeliac Disease: Gluten vs Placebo
NCT02472704 ·Status: COMPLETED ·Phase: NA
-
Intestinal Transglutaminase Antibodies in Celiac Disease Diagnosis
NCT05810441 ·Status: COMPLETED
-
Safety and Efficacy of ALV003 for the Treatment of Celiac Disease
NCT00959114 ·Status: COMPLETED ·Phase: PHASE2
-
Protocol for Correlating Enteropathic Severity and Small Intestinal CYP3A4 Activity in Patients With Celiac Disease
NCT01338324 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease
NCT07298343 ·Status: RECRUITING ·Phase: PHASE2
-
Gluten Sensor Device to Promote Gluten Free Diet Adherence and Quality of Life in Patients With Celiac Disease
NCT03321214 ·Status: COMPLETED ·Phase: NA
-
T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge
NCT04614571 ·Status: COMPLETED ·Phase: NA
-
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
NCT06557772 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Effect of Addition of Short Course of Prednisolone to Gluten Free Diet in Naive Celiac Disease Patients
NCT01045837 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study of PVP001, PVP002, and PVP003 in Healthy Adults and PVP001 and PVP002 in Adults With Celiac Disease
NCT03701555 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase II Study of CCX282-B in Patients With Celiac Disease
NCT00540657 ·Status: COMPLETED ·Phase: PHASE2
-
Virtual Dietetic Interventions in Patients With Coeliac
NCT07172555 ·Status: RECRUITING ·Phase: NA
-
Celiac Disease and Vitamin Status: Evaluation of the Effect of Supplementation With a Probiotic (VIVOMIXX®) in a Cohoort of Celiac Patients
NCT04160767 ·Status: UNKNOWN ·Phase: PHASE4
-
Risk of Celiac Disease and Age at Gluten Introduction
NCT00639444 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of Varying Methods of ALV003 Administration for the Treatment of Celiac Disease
NCT01255696 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Enzyme Supplements to Treat Celiac Disease
NCT00962182 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients
NCT01917630 ·Status: UNKNOWN ·Phase: PHASE2